Get your patients
started
with treatment
and support
for
SKYCLARYS

Patient with walker

Chris, age 42 | Fisherman, outdoorsman | Taking SKYCLARYS since 2023 | Chris is a paid spokesperson for Biogen.

Getting started

Dosing and administration

Testing and monitoring

Testing and monitoring patients before
and during SKYCLARYS treatment

Obtain ALT, AST, bilirubin, BNP, and lipid
parameters prior to initiating SKYCLARYS
and during treatment¹

Aminotransferases¹

Aminotransferases monitoring table

Monitor ALT, AST, and total bilirubin before starting SKYCLARYS. There were no cases of concomitant elevation of transaminases and total bilirubin observed in the clinical trial. Maximum increases in ALT and AST occurred within 12 weeks after starting SKYCLARYS. Increases in serum aminotransferases were generally asymptomatic and reversible following discontinuation of SKYCLARYS
If levels are >5x ULN, or >3x ULN with evidence of liver dysfunction, immediately discontinue SKYCLARYS and repeat liver function tests as soon as possible
If levels stabilize or resolve, SKYCLARYS may be reinitiated with an appropriate increased frequency of monitoring of liver function

ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal.

B-type natriuretic peptide (BNP)¹

BNP monitoring table

Monitor patients for the signs and symptoms of fluid overload, such as sudden weight gain (3 pounds or more of weight gain in one day or 5 pounds or more of weight gain in a week), peripheral edema, palpitations, and shortness of breath. Management of fluid overload and heart failure may require discontinuation of SKYCLARYS

Blood flow icon

Lipid abnormalities¹

Lipid abnormalities monitoring table

Manage lipid abnormalities according to clinical guidelines

Patient standing with a walker